Vascular endothelial growth factor (VEGF)-A is a key factor in the pathogenesis of choroidal neovascularization (CNV).6–8 Milestone clinical trials have demonstrated significant efficacy in terms of improving visual acuity (VA) with monthly injections of ranibizumab. Here, VEGFA is linked to choroidal neovascularization.